NYSE$BLCO
Bausch + Lomb Corp · Q4 2024 earnings
Q4 2024 earnings · · Before market open · Investor relations
Briefing
Bausch + Lomb reported revenue growth across all segments and geographies in Q4 2024, with strong performance in vision care and surgical businesses.
Bausch + Lomb delivered broad-based growth in Q4 2024, with total revenue increasing 9% to $1.28 billion. The vision care segment led the way, supported by strong demand for contact lenses and consumer products. The company also reported a reduction in net loss and an increase in operating income, reflecting improved profitability.
- Total revenue increased 9% year-over-year to $1.28 billion.
- Net loss narrowed to $3 million from $54 million in Q4 2023.
- Operating income improved to $87 million, up from $49 million in Q4 2023.
- Strong performance in vision care and surgical segments drove revenue growth.
Headline financials
Revenue & EPS history
Bausch + Lomb · Revenue · Quarterly
$1.28B
Revenue by segment
Bausch + Lomb · $1.01B total across 3 segments · Q3 2023
- Vision Care$648M+8.4%64.3%
- Surgical$185M+7.6%18.4%
- Pharmaceuticals$174M+1.2%17.3%
Forward guidance
Bausch + Lomb expects continued growth in 2025, with revenue projected between $4.95 billion and $5.05 billion, supported by strong performance in core segments.
Tailwinds
- Revenue growth expected in the range of 5.5% to 7.5% on a constant currency basis.
- Vision Care and Surgical segments continue to perform strongly.
- Acquisitions and product launches expected to drive growth.
- Investment in R&D to support long-term innovation.
- Improved operating leverage expected to enhance profitability.
Headwinds
- Foreign exchange headwinds expected to reduce revenue by approximately $100 million.
- Adjusted EBITDA impacted by $20 million due to currency fluctuations.
- Higher selling and marketing expenses may weigh on margins.
- Macroeconomic uncertainties could impact consumer demand.
- Increased competition in key markets poses a risk to market share.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2024
-1.0%
Avg return
Earnings day
-1.8%
Avg return
5 days after
-1.0%
Avg return
30 days after
43%
9 / 21 earnings
Positive
+18.7%
Q4 2023
Best reaction
-15.7%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.8% | +2.9% | -1.0% | |
| Q4 2025 | +0.2% | +1.5% | -11.3% | |
| Q3 2025 | +2.1% | +0.3% | +6.5% | |
| Q1 2025 | -15.7% | -17.1% | -16.4% | |
| Q4 2024 | -0.3% | -3.3% | -4.8% | |
| Q3 2024 | -2.3% | -4.3% | -4.5% | |
| Q2 2024 | -0.1% | -8.7% | -2.6% | |
| Q1 2024 | -4.7% | -0.7% | +5.5% | |
| Q4 2023 | +18.7% | +15.7% | +10.8% | |
| Q3 2023 | +4.6% | +2.9% | -4.3% | |
| Q2 2023 | -2.5% | -3.4% | -7.2% | |
| Q1 2023 | +0.1% | +4.6% | +4.4% | |
| Q4 2020 | +0.4% | -3.7% | -14.1% | |
| Q4 2022 | +0.4% | -3.7% | -14.1% | |
| Q3 2022 | -4.9% | +5.6% | +7.9% | |
| Q3 2021 | -4.9% | +5.6% | +7.9% | |
| Q2 2022 | +4.7% | +6.3% | +1.2% | |
| Q2 2021 | +4.7% | +6.3% | +1.2% | |
| Q1 2022 | -6.8% | -14.6% | +5.0% | |
| Q4 2021 | -6.8% | -14.6% | +5.0% | |
| Q1 2021 | -6.8% | -14.6% | +5.0% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro